Last reviewed · How we verify
NCT06872658: ICG-002
Study to Detect Dendritic Cell Recruitment in Human Retina
trial in Dry Age Related Macular Degeneration in 15 participants. Not yet recruiting.
1 November 2025
Quick facts
| Lead sponsor | MindImmune Therapeutics, Inc. |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 1 May 2025 |
| Primary completion | 1 November 2025 |
| Estimated completion | 1 January 2026 |
Conditions studied
- Dry Age Related Macular Degeneration — all drugs for Dry Age Related Macular Degeneration →
- Mild Cognitive Impairment (MCI) — all drugs for Mild Cognitive Impairment (MCI) →
- Alzheimer Disease — all drugs for Alzheimer Disease →
Sponsor
MindImmune Therapeutics, Inc.
Who can join
Adults 55 to 80, any sex, with Dry Age Related Macular Degeneration or Mild Cognitive Impairment (MCI). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to develop an optimal method to detect the immune cells (cells that protect the human body against diseases) in association with abnormal conditions of the retina (light sensitive tissue in the back of the eye) that will be relevant to diseases such as age related macular degeneration (AMD), mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD. The main objectives of this study are: 1. Establish Optimal Method for Retinal Imaging of Dendritic Cells (DCs) 2. Safety and Tolerability of ICG infusion in normal healthy, older adult volunteers, in participants with AMD (Dry AMD with Geographic Atrophy (GA)), and in participants who have received a diagnosis of either Mild Cognitive Impairment (MCI) due to AD, or mild AD
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06872658
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other MindImmune Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT05482867 — Exploratory Open Label Study for Development of a Method To Detect Dendritic Cells · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06872658 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MindImmune Therapeutics, Inc.
- Last refreshed: 12 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06872658.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing